Here, we present the data and rationale for the use of NT-proBNP, a biomarker that is analytically validated, clinically qualified, directly modulated by LC-elicited signal transduction pathways in cardiomyocytes and accepted by AL amyloidosis specialists as a surrogate end point for survival. The gene discussed is NPPB; the disease is AL amyloidosis.